Results 251 to 260 of about 553,081 (302)

Sucralose Promotes Benzo(a)Pyrene-Induced Renal Toxicity in Mice by Regulating P-glycoprotein. [PDF]

Antioxidants (Basel)
Hu J, Feng J, Bai Y, Yao ZS, Wu XY, Hong XY, Lu GD, Xue K.   +7 more
europepmc   +1 more source

Enhanced plasma and brain concentrations and medulloblastoma cytotoxicity of asciminib and nilotinib by P-glycoprotein inhibition with tariquidar. [PDF]

Anticancer Drugs
Thompson EM, Cheng L, Spasojevic I.
europepmc   +1 more source

Autotaxin regulates the expression and the activity of P-glycoprotein in lipopolysaccharide -activated microglial cells. [PDF]

Cytotechnology
Fayyad-Kazan M, Soayfane Z, Faour W, Fayyad-Kazan H, Awada R.   +4 more
europepmc   +1 more source

P-Glycoprotein Drives Glioblastoma Survival and Chemotherapy Resistance: Potential as a Promising Liquid Biopsy Biomarker. [PDF]

Am J Pathol
Pilotto Heming C, de Souza Barbosa I, Lyra Miranda R, Nogueira Ugarte O, Santório de São José V, Moura Neto V, Aran V.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

P-glycoprotein homologues

1994
Multidrug resistance (MDR) is defined by the simultaneous acquisition of cellular resistance to a broad range of cytotoxic compounds bearing little or no structural and functional homologies [1–5]. MDR is caused in cultured cells in vitro [6–9] and in tumor cells in vivo [10–12] by the overexpression of P-glycoprotein (Pgp) (reviewed in [13]).
E, Buschman, P, Lepage, P, Gros
openaire   +2 more sources

Functional intracellular P‐glycoprotein

International Journal of Cancer, 1998
Efflux of chemotherapy drugs by P-glycoprotein (P-gp) at the plasma membrane is thought to be a major cause of cancer multidrug resistance. In this report, we show by flow cytometry that P-gp also concentrates large amounts of 2 different drugs, Hoechst 33342 and daunorubicin, within a cytoplasmic compartment of multidrug resistant CHRC5 cells.
A B, Shapiro, K, Fox, P, Lee, Y D, Yang, V, Ling   +4 more
openaire   +2 more sources

Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors

Journal of Medicinal Chemistry, 2016
The first example of vinca derivatives 16-18 able to modulate P-glycoprotein (Pgp) efflux activity is reported. They were elaborated in two steps from vinorelbine 3 (VLN) by a modification of the velbenamine moiety. These compounds were able to decrease efficiently Pgp mediated influx and efflux of rhodamine-123 (Rho) and to restore the cytotoxicity of
Olga, Gherbovet, María Concepción, García Alvarez, Jérôme, Bignon, Fanny, Roussi   +3 more
openaire   +2 more sources

P-glycoprotein and multidrug resistance

Current Opinion in Genetics & Development, 1996
Although the phenomenon of simultaneous resistance to multiple cytotoxic drugs (multidrug resistance) in cancer cells has been discussed for more than two decades, and the human and mouse genes encoding an energy-dependent transporter (the multidrug transporter or P-glycoprotein) responsible for multidrug resistance were cloned 10 years ago, there is ...
M M, Gottesman, I, Pastan, S V, Ambudkar
openaire   +4 more sources

Photoaffinity substrates for P-glycoprotein

Biochemical Pharmacology, 1992
A variety of compounds can inhibit the function of P-glycoprotein (Pgp) by binding to it and preventing the efflux of anticancer drug substrates. While the molecular architecture of the drug binding site(s) in Pgp is not known, it is clear that modulators in general appear to conform to some general physical-chemical rules.
W T, Beck, X D, Qian
openaire   +2 more sources

The P-glycoprotein multidrug transporter

General Pharmacology: The Vascular System, 1996
1. P-glycoprotein (P-gp) is a transmembrane protein involved in ATP-dependent efflux of various structurally unrelated anticancer drugs. Its overexpression in cancer cells decreases intracellular drug concentrations and, thus, confers a multidrug resistance phenotype. 2.
O, Fardel, V, Lecureur, A, Guillouzo
openaire   +2 more sources